| POKORNÁ, Petra, Giannoula KLEMENT, Alžběta VAŠÍKOVÁ, Veronika KANDEROVÁ, Marta JEŽOVÁ, Kristýna NOSKOVÁ, Peter MÚDRY, Michal KÝR, Tomáš MERTA, Viera BAJČIOVÁ, Zdenka KŘENOVÁ, Hana PÁLOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Ondřej SLABÝ, Dalibor VALÍK and Jaroslav ŠTĚRBA. Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. JCO PRECISION ONCOLOGY. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2022, vol. 6, June 2022, p. 1-7. ISSN 2473-4284. Available from: https://dx.doi.org/10.1200/PO.21.00525. |
Other formats:
BibTeX
LaTeX
RIS
@article{1863363,
author = {Pokorná, Petra and Klement, Giannoula and Vašíková, Alžběta and Kanderová, Veronika and Ježová, Marta and Nosková, Kristýna and Múdry, Peter and Kýr, Michal and Merta, Tomáš and Bajčiová, Viera and Křenová, Zdenka and Pálová, Hana and Zdražilová Dubská, Lenka and Slabý, Ondřej and Valík, Dalibor and Štěrba, Jaroslav},
article_location = {PHILADELPHIA},
article_number = {June 2022},
doi = {http://dx.doi.org/10.1200/PO.21.00525},
keywords = {intermitent dosing lorlatinib; chemoresistant lymphoma; minimal disseminated disease; pediatric oncology},
language = {eng},
issn = {2473-4284},
journal = {JCO PRECISION ONCOLOGY},
title = {Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing},
url = {https://ascopubs.org/doi/full/10.1200/PO.21.00525},
volume = {6},
year = {2022}
}
TY - JOUR
ID - 1863363
AU - Pokorná, Petra - Klement, Giannoula - Vašíková, Alžběta - Kanderová, Veronika - Ježová, Marta - Nosková, Kristýna - Múdry, Peter - Kýr, Michal - Merta, Tomáš - Bajčiová, Viera - Křenová, Zdenka - Pálová, Hana - Zdražilová Dubská, Lenka - Slabý, Ondřej - Valík, Dalibor - Štěrba, Jaroslav
PY - 2022
TI - Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
JF - JCO PRECISION ONCOLOGY
VL - 6
IS - June 2022
SP - 1-7
EP - 1-7
PB - LIPPINCOTT WILLIAMS & WILKINS
SN - 24734284
KW - intermitent dosing lorlatinib
KW - chemoresistant lymphoma
KW - minimal disseminated disease
KW - pediatric oncology
UR - https://ascopubs.org/doi/full/10.1200/PO.21.00525
N2 - With the emergence of targeted therapies, the traditional maximum tolerated dosing where toxicities guide the treatment dose is no longer relevant. Especially in the case of tyrosine kinase inhibitors (TKIs), where higher doses lead to therapeutic resistance due to ligand or receptor upregulation and where off-target toxicities plague any increase of dose. In the case of TKIs, where the most effective dose is at the bottom of a U-shaped curve, therapy should be guided by biomarkers, or by minimal residual disease. We present a case of relapsed chemotherapy-refractory ALK-positive anaplastic large cell lymphoma treated with lorlatinib, where we used frequent minimal disseminated disease monitoring to guide the length of on/off therapy periods during intermitted dosing in order to prevent treatment resistance.
ER -
POKORNÁ, Petra, Giannoula KLEMENT, Alžběta VAŠÍKOVÁ, Veronika KANDEROVÁ, Marta JEŽOVÁ, Kristýna NOSKOVÁ, Peter MÚDRY, Michal KÝR, Tomáš MERTA, Viera BAJČIOVÁ, Zdenka KŘENOVÁ, Hana PÁLOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Ondřej SLABÝ, Dalibor VALÍK and Jaroslav ŠTĚRBA. Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. \textit{JCO PRECISION ONCOLOGY}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2022, vol.~6, June 2022, p.~1-7. ISSN~2473-4284. Available from: https://dx.doi.org/10.1200/PO.21.00525.
|
